{"success":true,"data":{"pressRelease":{"id":"165757","rtpr_id":"nGNX7Ym1vb-20261009","ticker":"GDTC","exchange":"NASDAQ","all_tickers":["GDTC","F98"],"title":"CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency","author":"Globe Newswire","published_at":"2026-10-09T20:30:00.161Z","article_body":"SINGAPORE, Oct. 09, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (the\n“Company”) (NASDAQ: GDTC), a Singapore-based clinical stage\nbiopharmaceutical company focused on harnessing its proprietary technologies\nto develop novel affordable donor-derived, cell-based allogeneic\nimmunotherapies, today announced that on October 6, 2026, the Company received\na notice from the staff of the Nasdaq Listing Qualifications department of The\nNasdaq Stock Market LLC (“Nasdaq”) stating that for the last 30\nconsecutive business days, the closing bid price of the Company’s ordinary\nshares (the “Ordinary Shares”) was below the minimum bid price of US$1.00\nper share requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq\nnotification letter has no current effect on the listing or trading of the\nCompany’s Ordinary Shares on Nasdaq.\n\nPursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided with a\ncompliance period of 180 calendar days, or until April 5, 2027, to regain\ncompliance under the Nasdaq Listing Rules. If at any time during the 180-day\ncompliance period, the closing bid price of the Company’s Ordinary Shares is\nUS$1.00 per share or higher for at least ten consecutive business days, Nasdaq\nwill provide the Company with written confirmation of compliance and the\nmatter will be closed. In the event the Company does not regain compliance by\nApril 5, 2027, subject to the determination by the staff of Nasdaq, the\nCompany may be eligible for an additional 180-day compliance period if it\nmeets the continued listing requirement for market value of publicly held\nshares and all other initial listing standards for The Nasdaq Capital Market,\nwith the exception of the minimum bid price requirement. In this case, the\nCompany will need to provide written notice of its intention to cure the\ndeficiency during the second compliance period, by effecting a reverse stock\nsplit, if necessary.\n\nThe Nasdaq notification letter does not affect the Company’s business\noperations, and the Company intends to take all reasonable measures to regain\ncompliance within the prescribed grace period.\n\nAbout CytoMed Therapeutics Limited (CytoMed)\n\nIncorporated in 2018, CytoMed was spun off from the Agency for Science,\nTechnology and Research (A*STAR), Singapore’s leading research and\ndevelopment agency in the public sector. CytoMed is a clinical stage\nbiopharmaceutical company focused on harnessing its licensed proprietary\ntechnologies, namely gamma delta T cell and iPSC-derived gamma delta Natural\nKiller T cell, to create novel cell-based allogeneic immunotherapies for the\ntreatment of various human cancers. The development of novel technologies has\nbeen inspired by the clinical success of existing CAR-T therapies in treating\nhaematological malignancies, as well as the current clinical limitations and\ncommercial challenges in extrapolating the CAR-T principle into the treatment\nof solid tumours. For more information, please visit www.cytomed.sg and follow\nus on Twitter (“X”) @CytomedSG, on LinkedIn, and Facebook.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements as defined by the\nPrivate Securities Litigation Reform Act of 1995. Forward-looking statements\ninclude statements concerning plans, objectives, goals, strategies, future\nevents or performance, and underlying assumptions and other statements that\nare other than statements of historical facts. When the Company uses words\nsuch as “may, “will, “intend,” “should,” “believe,”\n“expect,” “anticipate,” “project,” “estimate” or similar\nexpressions that do not relate solely to historical matters, it is making\nforward-looking statements. Forward-looking statements are not guarantees of\nfuture performance and involve risks and uncertainties that may cause the\nactual results to differ materially from the Company’s expectations\ndiscussed in the forward-looking statements. These statements are subject to\nuncertainties and risks including, but not limited to, the following: the\nCompany’s plans to develop and commercialize its product candidates; the\ninitiation, timing, progress and results of the Company’s current and future\npre-clinical studies and clinical trials and the Company’s R&D programs; the\nCompany’s estimates regarding expenses, future revenue, capital requirements\nand needs for additional financing; the Company’s ability to successfully\nacquire or obtain licenses for additional product candidates on reasonable\nterms; the Company’s ability to establish and maintain collaborations and/or\nobtain additional funding and assumptions underlying or related to any of the\nforegoing and other risks contained in reports filed by the Company with the\nSEC. For these reasons, among others, investors are cautioned not to place\nundue reliance upon any forward-looking statements in this press release.\nAdditional factors are discussed in the Company’s filings with the SEC,\nwhich are available for review at www.sec.gov. The Company undertakes no\nobligation to publicly revise these forward–looking statements to reflect\nevents or circumstances that arise after the date hereof.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy these securities, nor shall there be any sale of these\nsecurities in any jurisdiction in which such offer, solicitation or sale would\nbe unlawful prior to the registration or qualification under the securities\nlaws of any such jurisdiction.\n\nContact:\n\nCytoMed Therapeutics Limited\nenquiry@cytomed.sg\nAttention : Evelyn Tan, Chief Corporate Officer \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/077e953a-7922-47fd-95d5-9f73e6701608)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7Ym1vb-20261009","title":"CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency","author":"Globe Newswire","ticker":"GDTC","created":"2026-10-09T20:30:00.161Z","tickers":["GDTC","F98"],"exchange":"NASDAQ","article_body":"SINGAPORE, Oct. 09, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (the\n“Company”) (NASDAQ: GDTC), a Singapore-based clinical stage\nbiopharmaceutical company focused on harnessing its proprietary technologies\nto develop novel affordable donor-derived, cell-based allogeneic\nimmunotherapies, today announced that on October 6, 2026, the Company received\na notice from the staff of the Nasdaq Listing Qualifications department of The\nNasdaq Stock Market LLC (“Nasdaq”) stating that for the last 30\nconsecutive business days, the closing bid price of the Company’s ordinary\nshares (the “Ordinary Shares”) was below the minimum bid price of US$1.00\nper share requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq\nnotification letter has no current effect on the listing or trading of the\nCompany’s Ordinary Shares on Nasdaq.\n\nPursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided with a\ncompliance period of 180 calendar days, or until April 5, 2027, to regain\ncompliance under the Nasdaq Listing Rules. If at any time during the 180-day\ncompliance period, the closing bid price of the Company’s Ordinary Shares is\nUS$1.00 per share or higher for at least ten consecutive business days, Nasdaq\nwill provide the Company with written confirmation of compliance and the\nmatter will be closed. In the event the Company does not regain compliance by\nApril 5, 2027, subject to the determination by the staff of Nasdaq, the\nCompany may be eligible for an additional 180-day compliance period if it\nmeets the continued listing requirement for market value of publicly held\nshares and all other initial listing standards for The Nasdaq Capital Market,\nwith the exception of the minimum bid price requirement. In this case, the\nCompany will need to provide written notice of its intention to cure the\ndeficiency during the second compliance period, by effecting a reverse stock\nsplit, if necessary.\n\nThe Nasdaq notification letter does not affect the Company’s business\noperations, and the Company intends to take all reasonable measures to regain\ncompliance within the prescribed grace period.\n\nAbout CytoMed Therapeutics Limited (CytoMed)\n\nIncorporated in 2018, CytoMed was spun off from the Agency for Science,\nTechnology and Research (A*STAR), Singapore’s leading research and\ndevelopment agency in the public sector. CytoMed is a clinical stage\nbiopharmaceutical company focused on harnessing its licensed proprietary\ntechnologies, namely gamma delta T cell and iPSC-derived gamma delta Natural\nKiller T cell, to create novel cell-based allogeneic immunotherapies for the\ntreatment of various human cancers. The development of novel technologies has\nbeen inspired by the clinical success of existing CAR-T therapies in treating\nhaematological malignancies, as well as the current clinical limitations and\ncommercial challenges in extrapolating the CAR-T principle into the treatment\nof solid tumours. For more information, please visit www.cytomed.sg and follow\nus on Twitter (“X”) @CytomedSG, on LinkedIn, and Facebook.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements as defined by the\nPrivate Securities Litigation Reform Act of 1995. Forward-looking statements\ninclude statements concerning plans, objectives, goals, strategies, future\nevents or performance, and underlying assumptions and other statements that\nare other than statements of historical facts. When the Company uses words\nsuch as “may, “will, “intend,” “should,” “believe,”\n“expect,” “anticipate,” “project,” “estimate” or similar\nexpressions that do not relate solely to historical matters, it is making\nforward-looking statements. Forward-looking statements are not guarantees of\nfuture performance and involve risks and uncertainties that may cause the\nactual results to differ materially from the Company’s expectations\ndiscussed in the forward-looking statements. These statements are subject to\nuncertainties and risks including, but not limited to, the following: the\nCompany’s plans to develop and commercialize its product candidates; the\ninitiation, timing, progress and results of the Company’s current and future\npre-clinical studies and clinical trials and the Company’s R&D programs; the\nCompany’s estimates regarding expenses, future revenue, capital requirements\nand needs for additional financing; the Company’s ability to successfully\nacquire or obtain licenses for additional product candidates on reasonable\nterms; the Company’s ability to establish and maintain collaborations and/or\nobtain additional funding and assumptions underlying or related to any of the\nforegoing and other risks contained in reports filed by the Company with the\nSEC. For these reasons, among others, investors are cautioned not to place\nundue reliance upon any forward-looking statements in this press release.\nAdditional factors are discussed in the Company’s filings with the SEC,\nwhich are available for review at www.sec.gov. The Company undertakes no\nobligation to publicly revise these forward–looking statements to reflect\nevents or circumstances that arise after the date hereof.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy these securities, nor shall there be any sale of these\nsecurities in any jurisdiction in which such offer, solicitation or sale would\nbe unlawful prior to the registration or qualification under the securities\nlaws of any such jurisdiction.\n\nContact:\n\nCytoMed Therapeutics Limited\nenquiry@cytomed.sg\nAttention : Evelyn Tan, Chief Corporate Officer \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/077e953a-7922-47fd-95d5-9f73e6701608)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-09T20:30:00.212866552Z","server_sent_at_ms":1791577800212},"received_at":"2026-10-09T20:30:00.312Z","source_url":null},"analysis":{"id":"154147","press_release_id":"165757","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["trading below Nasdaq US$1.00 minimum bid price for 30 consecutive business days","possible reverse stock split if compliance not regained by April 5, 2027"],"eventType":"regulatory","narrative":"CytoMed Therapeutics received a Nasdaq notice that its closing bid price has been below the US$1.00 minimum for 30 consecutive business days.\n\nThe company has 180 days, until April 5, 2027, to regain compliance by closing at or above US$1.00 for ten consecutive business days.\n\nThere is no current effect on trading, but failure to cure could force a reverse stock split or delisting risk; the notice does not affect business operations.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Micro-cap biotech GDTC faces Nasdaq deficiency notice with reverse-split risk if shares don't recover to $1 by April 2027."},"keyFigures":{"customDimensions":{"min_bid_price":"US$1.00","deficient_days":30,"compliance_deadline":"April 5, 2027","compliance_period_days":180}},"namedEntities":{"people":[{"name":"Evelyn Tan","role":"Chief Corporate Officer"}],"products":[],"companies":[{"name":"CytoMed Therapeutics Limited","ticker":"GDTC"},{"name":"Nasdaq Stock Market LLC","relationship":"exchange/regulator"},{"name":"Agency for Science, Technology and Research (A*STAR)","relationship":"parent/spin-off source"}],"dollarAmounts":[{"amount":"US$1.00","context":"Nasdaq minimum bid price per share requirement"}]},"materialImpact":{"score":3,"reasoning":"Nasdaq minimum bid price deficiency notice signals listing-compliance risk for a small-cap clinical-stage biotech, with potential reverse split if compliance is not regained by April 5, 2027. No immediate effect on listing, but a meaningful negative overhang."},"tickerRelevance":{"others":[],"primary":"GDTC"},"globalImportance":22,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"listing-compliance-notice","sectorWeight":"clinical-stage-biotech","issuerAuthored":true}},"event_type":"regulatory","event_type_secondary":null,"sentiment":"bearish","material_impact_score":3,"narrative":"CytoMed Therapeutics received a Nasdaq notice that its closing bid price has been below the US$1.00 minimum for 30 consecutive business days.\n\nThe company has 180 days, until April 5, 2027, to regain compliance by closing at or above US$1.00 for ten consecutive business days.\n\nThere is no current effect on trading, but failure to cure could force a reverse stock split or delisting risk; the notice does not affect business operations.","key_figures":{"customDimensions":{"min_bid_price":"US$1.00","deficient_days":30,"compliance_deadline":"April 5, 2027","compliance_period_days":180}},"named_entities":{"people":[{"name":"Evelyn Tan","role":"Chief Corporate Officer"}],"products":[],"companies":[{"name":"CytoMed Therapeutics Limited","ticker":"GDTC"},{"name":"Nasdaq Stock Market LLC","relationship":"exchange/regulator"},{"name":"Agency for Science, Technology and Research (A*STAR)","relationship":"parent/spin-off source"}],"dollarAmounts":[{"amount":"US$1.00","context":"Nasdaq minimum bid price per share requirement"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-09T20:30:04.811Z","global_importance":22,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"listing-compliance-notice","sectorWeight":"clinical-stage-biotech","issuerAuthored":true}},"durationMs":4416,"modelName":"glm-5.3-flashx"}}